Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2022

Genmab — December 2022

Planlagt Fastgjort Låst Flyttet Genmab
668 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #108

    that wasn't exactly what i had in mind lol

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #109

      Julerally på aktiemarkedet? På de sociale aktiemedier og finansmedier bliver der lige nu gættet på livet løs om, hvorvidt vi kommer til at se et julerally i år. Hvad tror Helge Larsen? Og hvorfor? Derudover kommer han ind på Equinor, laksesektoren, Anavex og Genmab. https://www.proinvestor.com/boards/108513

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #110

        Hej Dublo, Jeg står op før kl. 5, men starter normalt først på Proinvestor kl. 6. Nyd din ferie, hvor end du er. 🙂

        1 Reply Last reply
        0
        • G Offline
          G Offline
          GeorgeBest
          wrote on sidst redigeret af
          #111

          ph I/II epcoritamab + R-DHAX transplant-eligible r/r DLBCL (n=29)

          • most common AEs hematologic, CRS (mild)
          • pts ➡️ ASCT ORR 100%
          • non-ASCT pts (mostly pt choice) ORR 64%
            fascinating data for the combination https://twitter.com/chanyooncheah/status/1600890760546914304?s=61&t=kTAfbfq899c3srDizGwYoA
          1 Reply Last reply
          0
          • D Offline
            D Offline
            Doublo
            wrote on sidst redigeret af
            #112

            God morgen fra Tyrkiet klart du må starte før kl. 5 Helge,
            eller kunne du slet ikke nå det du når.

            1 Reply Last reply
            0
            • Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktørH Offline
              Helge_LarsenPI-redaktør
              wrote on sidst redigeret af
              #113

              Godmorgen 🙂

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Stroka
                wrote on sidst redigeret af
                #114

                God morgen 🙂

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  GeorgeBest
                  wrote on sidst redigeret af
                  #115

                  #ASH22 Talquetamab, a GPRC5D x CD3 Bispecific Antibody, in Patients with RRMM. At 0.4 mg/kg/week: ORR 73%, median PFS 7.5 months. https://twitter.com/transplant_doc/status/1600722580859949056?s=61&t=xzQrHseV4vIwvZlzzdG0vA

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #116

                    Genmab rider på en bølge af succes

                    David Mygind
                    Fredag 09. december https://ugebrev.dk/life-science/genmab-rider-paa-en-boelge-af-succes/

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #117

                      "Genmab: Præsenterede torsdag data for Gen1042 der var bedre end forventet" https://www.jyskebank.dk/finansnyt/morgennyt/2f4f3c0d-af87-4ffd-94d0-47e163666bb1 -I still can't find anything about it; we'll probably have to wait for the R&D day

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #118

                        Nsclc er en svær øvelse https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2022/12/08195320/Ipsen-Contact-Press-Release-12-2022-1.pdf

                        1 Reply Last reply
                        0
                        • nohopeN Offline
                          nohopeN Offline
                          nohope
                          wrote on sidst redigeret af
                          #119

                          The problem with Mygind is that according to him then is the sky over Genmab is not just always blue, it is luminiscent.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            GeorgeBest
                            wrote on sidst redigeret af
                            #120

                            Well, the sky has been quite blue the last 10 years. Why would you make it grey then?

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #121

                              The sky above nohope is always black.

                              1 Reply Last reply
                              0
                              • StockBullS Offline
                                StockBullS Offline
                                StockBull
                                wrote on sidst redigeret af
                                #122

                                Im ok with the moon

                                1 Reply Last reply
                                0
                                • nohopeN Offline
                                  nohopeN Offline
                                  nohope
                                  wrote on sidst redigeret af
                                  #123

                                  You are probably right, we have to go back 10 years to make it look great.I can´t do 10 years, but this 5 years compared to Novo, which steadily pays annual dividend.https://imgur.com/a/DSOpp2a

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    GeorgeBest
                                    wrote on sidst redigeret af
                                    #124

                                    5 years looks okay for. Can I get the same return the next 5 years, I’ll be happy 🙂

                                    1 Reply Last reply
                                    0
                                    • J Offline
                                      J Offline
                                      JKY_VH
                                      wrote on sidst redigeret af
                                      #125

                                      😄 Bulder

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #126

                                        Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.prnewswire.com/news-releases/janssen-submits-biologics-license-application-to-us-fda-for-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-301699241.html

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #127

                                          just a year after teclistamab; that was dec21 (and approved oct22)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper